Error in Figure 1 - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Inaccuracy in Figure 1B of the Original Investigation on Dual Immune Checkpoint Inhibition in Rectal Cancer

  • October 5, 2026

Share

Clinical Scorecard: Correction Notice: Inaccuracy in Figure 1B of the Original Investigation on Dual Immune Checkpoint Inhibition in Rectal Cancer

At a Glance

CategoryDetail
ConditionRectal Cancer
Key MechanismsDual Immune Checkpoint Inhibition
Target PopulationPatients with rectal cancer undergoing neoadjuvant treatment
Care SettingClinical trial setting

Key Highlights

  • source_attribution

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with rectal cancer

          Involves dual immune checkpoint inhibition and neoadjuvant chemoradiotherapy

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Error in Figure 1

            • October 5, 2026

            Related Content

            MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

            Sex, Age, and Tumor Genetics to Inform Risk Stratification in Papillary Thyroid Cancer

            Reading Skin Cancer’s Molecular Fingerprint

            Machine-learning models analyzed Raman spectra to distinguish cancerous tissue from normal skin

            • October 6, 2026

            • 2 min